Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer

NCT00361244 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00361244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00361244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2006
Completion date
August 31, 2010
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma